Astria Therapeutics was acquired by BioCryst Pharmaceuticals. To see what’s new, visit biocryst.com
February 2023: AAAAI Annual Meeting
Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema, in Healthy Adult Subjects Followed for at Least 3 Months
November 2022: ACAAI Annual Scientific Meeting
Modeling and Simulation Predicts Robust HAE Attack Suppression with Every 3 Month Dosing of STAR-0215
July 2022: EAACI Annual Congress
STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrates Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys
July 2022: EAACI Annual Congress
STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE
April 2022: Fc Receptor and IgG Targeted Therapies Conference
Development of STAR-0215: PKPD Model of STAR-0215, an Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE
February 2022: AAAAI Annual Meeting
STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE
Nov. 2021: ACAAI Annual Scientific Meeting
STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for the Potential Treatment of HAE
Oct. 2021: NORD Summit
Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients